lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== Indirect size measurement of intact complexes === Sedimentation-velocity analytical ultracentrifugation (measures the translational diffusion constant) Dynamic light scattering (measures the translational diffusion constant) Pulsed-gradient protein nuclear magnetic resonance (measures the translational diffusion constant) Fluorescence polarization (measures the rotational diffusion constant) Dielectric relaxation (measures the rotational diffusion constant) Dual polarisation interferometry (measures the size and the density of the complex) Methods that measure the mass or volume under unfolding conditions (such as MALDI-TOF mass spectrometry and SDS-PAGE) are generally not useful, since non-native conditions usually cause the complex to dissociate into monomers. However, these may sometimes be applicable; for example, the experimenter may apply SDS-PAGE after first treating the intact complex with chemical cross-link reagents.
==== Misinterpretation of data ==== Some research groups initially reported that they had replicated the Fleischmann and Pons results but later retracted their reports and offered an alternative explanation for their original positive results. A group at Georgia Tech found problems with their neutron detector, and Texas A&M discovered bad wiring in their thermometers. These retractions, combined with negative results from some famous laboratories, led most scientists to conclude, as early as 1989, that no positive result should be attributed to cold fusion.
The Spanish Armed Forces issues an individual meal pack, available in 5 different menus, comprising a small cardboard box overwrapped with drab green polyethylene. Inside are 3 canned meals, plus accessories. Typical contents (Menu B) include: stewed steak, pickled mackerel, liver pâté with red peppers, an envelope of instant soup, a can of fruit, 2 salt tablets, 2 water purification tablets, a large multivitamin tablet, 10 sheets of general purpose paper, a book of matches, a folding can opener, a small folding ration heater and 2 fuel tablets, and an instruction sheet in three languages (Spanish, English and French). Crackers or bread are issued separately.
Sources: en.wikipedia.org
Hyperinsulinemia due to insulin resistance may occur in individuals with normal glucose levels and therefore is not diagnosed with usual tests. Hyperinsulinemia precedes prediabetes and diabetes that are characterized by hyperglycemia. Insulin resistance can be diagnosed by measures of plasma insulin, both fasting or during a glucose tolerance test. The use of fasting insulin to identify patients at risk has been proposed, but is currently not commonly used in clinical practice. The implications of hyperinsulinemia is the risk of comorbidities related to diabetes that may precede changes in blood glucose, including cardiovascular diseases.
== Metal recovery == Metal recovery is the final step in a hydrometallurgical process, in which metals suitable for sale as raw materials are produced. Sometimes, however, further refining is needed to produce ultra-high purity metals. The main types of metal recovery processes are electrolysis, gaseous reduction, and precipitation. For example, a major target of hydrometallurgy is copper, which is conveniently obtained by electrolysis. Cu2+ ions are reduced to Cu metal at low potentials, leaving behind contaminating metal ions such as Fe2+ and Zn2+.
Apart from the failed Third Period policy in the early 1930s, Marxist–Leninists played an important role in anti-fascist resistance movements, with the Soviet Union contributing to the Allied victory in World War II. In accordance with the three-power Yalta Agreement (4–11 February 1945), the Soviet Union purged native fascist collaborators and these in collaboration with the Axis Powers from the Eastern European countries occupied by the Axis Powers and installed native Marxist–Leninist governments.
=== Chiral chemistry === Applying the ideas above, chirality of organometallic compounds can be deduced as well with this technique. Each chiral compound has its own unique properties and binding mechanisms that are comparable to each other, which leads to differences in thermodynamic properties. By binding chiral solutions in a binding site can deduce the type of chirality and depending on the purpose, which chiral compound is more suitable for binding.
Sources: en.wikipedia.org
=== Sports management === Little has been prominently involved in Australian professional sport. Initially in motor racing, Little sponsored John Sidney Racing and Anthony Tratt's Porsche racing team. In 1998 Tratt's team moved into V8 Supercars under Little's ownership as Paul Little Racing. The team folded in 2005 after eight seasons of racing. Little also personally raced competitively but was discouraged by his fellow board members at Toll Holdings due to the danger. On 29 July 2013, Little became the chairman of the Essendon Football Club in the AFL, replacing David Evans. He served in the role for almost two and a half years, presiding over a turbulent time in the club's history as it faced allegations of running a program of illegal supplements during David Evans' tenure. Little stepped down on 14 December 2015, shortly before the final guilty verdict was returned in the supplements investigation, and was replaced by Lindsay Tanner.
== Pharmaceutical and legal impact == In the United States, the first company to develop a drug ("pioneer") must demonstrate that the drug is safe and effective by extensive and expensive trials. After that, there would be a period of exclusive rights to sell the drug, after which other companies ("generics") can market the same drug as a generic chemical under the Abbreviated New Drug Application. The pioneer companies often attempt to evergreen the patent drug by many methods. Since the appearance of generics can decrease the revenue rate of patented drugs by as much as 80%, this is very profitable. When disappearing polymorphs are involved, it is sometimes true that the pioneer company first discovered and patented polymorph A, then polymorph B, but polymorph A inevitably converts to polymorph B when seeded with microscopic amounts of B. This then means that later companies, even if they follow all the steps specified by the pioneering patent, end up with a polymorph B. Since with disappearing polymorphism, it is practically impossible for anyone to produce the original drug without it turning into the new one, producers are effectively barred from selling generics until the patent for the new polymorph has run out. Alternatively, they may try to argue that a new polymorph needs to undergo the same trials as new drugs, potentially delaying release of a generic for years.
== Geography == According to the United States Census Bureau, the borough had a total area of 2.07 square miles (5.36 km2), including 2.07 square miles (5.35 km2) of land and 0.01 square miles (0.01 km2) of water (0.24%). It rests on land originally inhabited by the Munsee-Delaware. The borough, a suburb of New York City, borders the Bergen County municipalities of Alpine, Bergenfield, Demarest, Dumont and Tenafly.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.